Attached files

file filename
EX-31.1 - EX-31.1 - T2 Biosystems, Inc.ttoo-20160630ex311a320b0.htm
EX-32.2 - EX-32.2 - T2 Biosystems, Inc.ttoo-20160630ex3225d6c54.htm
EX-31.2 - EX-31.2 - T2 Biosystems, Inc.ttoo-20160630ex3128d28ac.htm
EX-10.4 - EX-10.4 - T2 Biosystems, Inc.ttoo-20160630ex1048bf625.htm
EX-10.3 - EX-10.3 - T2 Biosystems, Inc.ttoo-20160630ex103b6b95c.htm
10-Q - 10-Q - T2 Biosystems, Inc.ttoo-20160630x10q.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

 

18 U.S.C. SECTION 1350,

 

AS ADOPTED PURSUANT TO

 

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of T2 Biosystems, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John McDonough, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

 

/s/ John McDonough

 

John McDonough

 

President and Chief Executive Officer

 

 

Date: August 8, 2016

 

This certification accompanies each Report pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by §906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.